What tablet strengths and dosing options are available for tamsulosin and silodosin (α‑blockers for benign prostatic hyperplasia)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Available Tablet Strengths for Tamsulosin and Silodosin

Tamsulosin is available as 0.4 mg capsules taken once daily, while silodosin is available in both 4 mg and 8 mg capsules, with 8 mg being the standard dose and 4 mg reserved for patients with moderate renal impairment.

Tamsulosin Dosing

  • Standard dose: 0.4 mg capsule once daily 1
  • Administration: Should be taken with a meal to optimize absorption and minimize side effects 1
  • The 0.4 mg formulation is the only FDA-approved strength for BPH treatment

Important Pharmacokinetic Considerations for Tamsulosin

Taking tamsulosin under fasted conditions results in a 30% increase in bioavailability and 40-70% increase in peak concentrations compared to fed conditions 1. This is why consistent administration with food is recommended—it provides more predictable drug levels and reduces the risk of orthostatic hypotension.

Silodosin Dosing

  • Standard dose: 8 mg capsule once daily with a meal 2
  • Reduced dose: 4 mg capsule once daily with a meal for patients with moderate renal impairment (creatinine clearance 30-50 mL/min) 2
  • Contraindicated: In severe renal impairment (creatinine clearance <30 mL/min) 2

Key Dosing Distinctions

Silodosin requires mandatory dose adjustment based on renal function, while tamsulosin does not. This makes pre-treatment assessment of renal function essential when considering silodosin 2. Both medications are also contraindicated in severe hepatic impairment 2.

Clinical Efficacy Context

Both agents demonstrate comparable efficacy in reducing LUTS symptoms 3. The 2023 European Association of Urology guidelines support the use of both alpha-blockers for BPH management 3. Research shows silodosin 4 mg twice daily (8 mg total daily dose) is non-inferior to tamsulosin 0.2 mg once daily in Asian populations 4, though Western dosing uses 0.4 mg tamsulosin.

Critical Safety Difference

Silodosin has a significantly higher rate of ejaculatory dysfunction (retrograde ejaculation) compared to tamsulosin—approximately 26 times higher versus placebo 5 and 6 times higher versus tamsulosin 5. This occurs in the majority of silodosin-treated patients but is reversible upon discontinuation 2.

Common Pitfalls to Avoid

  • Do not use silodosin 8 mg in patients with moderate renal impairment—this requires dose reduction to 4 mg 2
  • Always check renal function before prescribing silodosin, as it is contraindicated in severe renal disease 2
  • Counsel patients about ejaculatory dysfunction before starting silodosin—this affects quality of life and medication adherence 2
  • Ensure both medications are taken with food to optimize absorption and minimize orthostatic hypotension 2, 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.